

PRODUCT INFORMATION



PD 166326

Item No. 9000988

CAS Registry No.: 185039-91-2
Formal Name: 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one

MF: C₂₁H₁₆Cl₂N₄O₂

FW: 427.3


Purity: ≥95%

UV/Vis.: λ_{max}: 212, 259, 307, 362 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PD 166326 is supplied as a crystalline solid. A stock solution may be made by dissolving the PD 166326 in the solvent of choice, which should be purged with an inert gas. PD 166326 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of PD 166326 in these solvents is approximately 25 and 30 mg/ml, respectively.

PD 166326 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PD 166326 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PD 166326 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PD 166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC₅₀ = 8 nM) and Bcr/Abl-dependent cell growth (IC₅₀ = 0.4 nM).^{1,2} In addition to targeting a select group of receptor tyrosine kinases, PD 166326 also potently inhibits c-src (IC₅₀ = 6 nM).² Orally administered PD 166326 is well tolerated and effectively blocks Bcr/Abl kinase activity *in vivo*.³ Moreover, PD 166326 affects a distinct set of kinases from those targeted by imatinib mesylate (STI571) and can reduce the growth of some imatinib-resistant cells both *in vitro* and *in vivo* in animal models of chronic myelogenous leukemia.²⁻⁴

References

1. Wisniewski, D., Lambek, C.L., Liu, C., *et al.* Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. *Cancer Res.* **62(15)**, 4244-4255 (2002).
2. Huron, D.R., Gorre, M.E., Kraker, A.J., *et al.* A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. *Clin. Cancer Res.* **9(4)**, 1267-1273 (2003).
3. Wolff, N.C., Veach, D.R., Tong, W.P., *et al.* PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. *Blood* **105(10)**, 3995-4003 (2005).
4. Azam, M., Nardi, V., Shakespeare, W.C., *et al.* Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. *Proc. Natl. Acad. Sci. USA* **103(24)**, 9244-9249 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/29/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM